Cardiac dysfunction, which involves direct effects of the treatment on heart function and structure [7], is a well-established side effect from the use of conventional cardiotoxic drugs such as anthracyclines (the cornerstone of BC chemotherapy) and trastuzumab (the standard of care for the treatment of human epidermal growth factor receptor 2 (HER2)-positive) in BC treatment [8]. This evidence concerns the gene ERBB2 and breast cancer.